[Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities]

At present, there is debate regarding the continuous use of phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Cumulative evidence supports the benefit, even at low doses, thatcontinuous treatment has on erectile function -even in difficult-to-treat patients-, and on the spontaneity and naturalness of sexual relationships. Safety and tolerability have also proven to be good. Beyond phosphodiesterase 5 inhibition, the effect of continuous treatment of erectile function appears to be based on improvement of endothelial function and oxygenation of the penile vascular bed as a result of the increased number of erections, hence playing down the importance of pharmacokinetics. Although evidence is still limited, this new scenario opens new paths for the treatment of erectile dysfunction patients in whom on-demand treatments are not effective or deemed appropriate, and would benefit the spontaneity of sexual life.

Revista internacional de andrologia. 2017 Aug 12 [Epub]

Ana María Puigvert, Rafael Prieto, Ferran García

Instituto de Andrología y Medicina Sexual (IANDROMS), Barcelona, España. Electronic address: ., Unidad de Andrología, Medicina Sexual y Reproductiva, Hospital Regional Universitario Reina Sofía, Córdoba, España., Unidad de Andrología, Servicio de Reproducción, Instituto Marqués, Barcelona, España.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe